Exclusive Summary

• - Originator patents expired long ago with no active global IP barriers; generics have been widely marketed since the early 2000s, enabling fast distribution-led entry.
• - Listed on the WHO Essential Medicines List and in the AWaRe Access group, covering high-burden inpatient uses (pneumonia, SSTIs, bites, perioperative) with steady, inelastic demand.
• - Parenteral formulation typically qualifies for BE waiver; dual strengths (0.5g:0.1g and 1g:0.2g) fit multi-department use and tenders, reducing registration time and clinical burden.
• - Despite many generics, periodic clavulanate supply constraints create shortages; reliable supply plus hot-climate stability/longer shelf-life builds differentiation.
• - Versus the originator, 60–90% price reductions are achievable (market- and tender-dependent), aligning with public procurement and cost-sensitive markets.